Investors sold shares of Retrophin Inc (NASDAQ:RTRX) on strength during trading hours on Tuesday. $3.97 million flowed into the stock on the tick-up and $13.99 million flowed out of the stock on the tick-down, for a money net flow of $10.02 million out of the stock. Of all stocks tracked, Retrophin had the 26th highest net out-flow for the day. Retrophin traded up $0.04 for the day and closed at $23.78
A number of equities research analysts have recently issued reports on RTRX shares. ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Zacks Investment Research cut shares of Retrophin from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 14th. Finally, BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a report on Saturday, December 30th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. Retrophin currently has a consensus rating of “Hold” and an average price target of $44.00.
The stock has a market capitalization of $937.47, a P/E ratio of -15.75 and a beta of 1.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3226651/traders-sell-shares-of-retrophin-rtrx-on-strength-rtrx.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.